Stereotactic body radiation therapy for sarcoma pulmonary metastases Journal Article

Authors: Lebow, E. S.; Lobaugh, S. M.; Zhang, Z.; Dickson, M. A.; Rosenbaum, E.; D'Angelo, S. P.; Nacev, B. A.; Shepherd, A. F.; Shaverdian, N.; Wolden, S.; Wu, A. J.; Gelblum, D. Y.; Simone, C. B. 2nd; Gomez, D. R.; Alektiar, K.; Tap, W. D.; Rimner, A.
Article Title: Stereotactic body radiation therapy for sarcoma pulmonary metastases
Abstract: Background/Purpose: Stereotactic body radiation therapy (SBRT) is standard for patients with inoperable early-stage NSCLC. We hypothesized that SBRT for sarcoma pulmonary metastases would achieve high rates of local control with acceptable toxicity and that patients with oligometastatic disease may achieve prolonged survival following SBRT. Materials/Methods: This retrospective review included consecutive patients at our institution treated with SBRT for sarcoma pulmonary metastases. Cumulative incidence of local failure (LF) was estimated using a competing risks framework. Results: We identified 66 patients treated to 95 pulmonary metastases with SBRT. The median follow-up from the time of SBRT was 36 months (95% CI 34 – 53 months). The cumulative incidence of LF at 12 and 24 months was 3.1% (95% CI 0.9 – 10.6%) and 7.4% (95% CI 4.0% - 13.9%), respectively. The 12- and 24-month overall survival was 74% (95% CI 64 – 86%) and 49% (38 – 63%), respectively. Oligometastatic disease, intrathoracic only disease, and performance status were associated with improved survival on univariable analysis. Three patients had grade 2 pneumonitis, and one patient had grade 2 esophagitis. No patients had ≥ grade 3+ toxicities. Conclusion: To the best of our knowledge, this is the largest series of patients treated with SBRT for pulmonary sarcoma metastases. We observed that SBRT offers an effective alternative to surgical resection with excellent local control and low proportions of toxicity. © 2023 Elsevier B.V.
Keywords: adult; cancer survival; middle aged; treatment failure; major clinical study; overall survival; systemic therapy; cancer patient; cancer radiotherapy; follow up; esophagitis; cohort analysis; retrospective study; risk factor; pneumonia; sarcoma; lung metastasis; patient safety; cancer control; stereotactic body radiation therapy; thorax disease; performance; sbrt; cumulative incidence; pulmonary metastases; immune checkpoint inhibitor; disease burden; human; male; female; article; oligometastatic; ablative radiation therapy; bronchopulmonary sarcoma
Journal Title: Radiotherapy and Oncology
Volume: 187
ISSN: 0167-8140
Publisher: Elsevier Inc.  
Date Published: 2023-10-01
Start Page: 109824
Language: English
DOI: 10.1016/j.radonc.2023.109824
PUBMED: 37532104
PROVIDER: scopus
Notes: Article -- Source: Scopus
Citation Impact
MSK Authors
  1. Zhigang Zhang
    383 Zhang
  2. Daphna Y Gelblum
    184 Gelblum
  3. Kaled M Alektiar
    317 Alektiar
  4. Suzanne L Wolden
    530 Wolden
  5. Daniel R Gomez
    178 Gomez
  6. Sandra Pierina D'Angelo
    225 D'Angelo
  7. Andreas Rimner
    478 Rimner
  8. Abraham Jing-Ching Wu
    354 Wu
  9. Mark Andrew Dickson
    151 Dickson
  10. William Douglas Tap
    306 Tap
  11. Benjamin Alexander Nacev
    29 Nacev
  12. Charles Brian Simone
    116 Simone
  13. Stephanie Marie Lobaugh
    46 Lobaugh
  14. Emily Schapira Lebow
    37 Lebow